AbGn-168

AbGn-168 · Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AbGn-168, covering 2013-11-01 to 2013-11-01. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis [Phase 1]